Drug Profile
Lisavanbulin - Basilea Pharmaceutica
Alternative Names: B553; BAL 101553Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica
- Developer Basilea Pharmaceutica; The Adult Brain Tumor Consortium
- Class Antineoplastics; Imidazoles; Oxadiazoles; Small molecules
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma; Solid tumours
- No development reported Brain cancer; Breast cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Glioblastoma(First-line therapy) in USA (PO)
- 04 Jul 2023 Efficacy data from a phase I/IIa trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 02 Jun 2023 Efficacy and adverse events data from a phase I trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)